Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 50000615
Displayed 1 to 50 (of 81 total ) | Next | Last >>
Affinity DataIC50: 5nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 8nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 12nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 19nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 21nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 24nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 26nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 31nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 35nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 40nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 50nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 53nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 56nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 60nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 69nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 70nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 79nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 83nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 83nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 110nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 140nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 150nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 150nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 210nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 330nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 340nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 390nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataEC50: 410nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair
Affinity DataIC50: 660nMAssay Description:Inhibition of CHK1 (unknown origin)More data for this Ligand-Target Pair
Affinity DataEC50: 840nMAssay Description:Inhibition of CHK1 in human HT29 cells assessed as abrogation of camptothecin-induced G2/M phase arrestMore data for this Ligand-Target Pair


3D Structure (crystal)

























